Status:
COMPLETED
The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain
Lead Sponsor:
Virginia Commonwealth University
Conditions:
Neuropathic Pain
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study will test whether treatment with N-acetyl-L-cysteine (NAC) is safe and decreases pain in patients with chronic neuropathic pain. The investigators hypothesize that NAC will be a useful adju...
Detailed Description
This is an open-label study to evaluate the safety and efficacy of N-acetyl-L-cysteine in patients with Chronic neuropathic pain.
Eligibility Criteria
Inclusion
- 18-65 years old
- non-cancer neuropathic pain
- stable dose of opioids for pain
- using breakthrough pain meds
- still with persistent pain per VAS
Exclusion
- pregnant or nursing
- serious medical or psychiatric illness (including uncontrolled hypertension)
- active stomach ulcer, history or seizures or asthma
- breakthrough pain meds other than opioids
- using illicit drugs
Key Trial Info
Start Date :
January 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2017
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT01840345
Start Date
January 1 2014
End Date
April 1 2017
Last Update
May 14 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virginia Commonwealth University
Richmond, Virginia, United States, 23298